Registration Dossier
Registration Dossier
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 201-283-5 | CAS number: 80-48-8
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data

Acute Toxicity: oral
Administrative data
- Endpoint:
- acute toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 09 May 2017 to 06 June 2017
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 017
- Report date:
- 2017
Materials and methods
Test guidelineopen allclose all
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 423 (Acute Oral toxicity - Acute Toxic Class Method)
- Version / remarks:
- OECD Guidelines for Testing of Chemicals No. 423. Acute Oral Toxicity – Acute Toxic Class Method. Adopted: 17 December 2001
- Deviations:
- yes
- Remarks:
- See "Any other information" for details
- Qualifier:
- according to guideline
- Guideline:
- EU Method B.1 tris (Acute Oral Toxicity - Acute Toxic Class Method)
- Version / remarks:
- Commission Regulation (EC) No 440/2008 of 30 May 2008, B.1.tris
- Deviations:
- yes
- Remarks:
- See "Any other information" for details
- Qualifier:
- according to guideline
- Guideline:
- EPA OPPTS 870.1100 (Acute Oral Toxicity)
- Version / remarks:
- EPA Health Effects Test Guidelines (OPPTS 870.1100), United States, EPA 712-C-98-190 (1998)
- Deviations:
- yes
- Remarks:
- See "Any other information" for details
- GLP compliance:
- yes (incl. QA statement)
- Test type:
- acute toxic class method
- Limit test:
- no
Test material
- Reference substance name:
- Methyl toluene-4-sulphonate
- EC Number:
- 201-283-5
- EC Name:
- Methyl toluene-4-sulphonate
- Cas Number:
- 80-48-8
- Molecular formula:
- C8H10O3S
- IUPAC Name:
- methyl 4-methylbenzene-1-sulfonate
- Test material form:
- solid
- Details on test material:
- Name: PTSM
Chemical name: Methyl toluene-4-sulphonate
CAS number: 80-48-8
Batch/Lot Number: 609271
Description: White to pale yellow solid
Expiry Date: 01 March 2018
Purity: 99.7%
Storage Conditions: Room temperature
Safety precautions: Routine safety precautions (lab coat, gloves, safety glasses, face mask) for unknown materials were applied to assure personnel health and safety.
Constituent 1
- Specific details on test material used for the study:
- No further details specified in the study report.
Test animals
- Species:
- rat
- Strain:
- Wistar
- Sex:
- female
- Details on test animals or test system and environmental conditions:
- Species and strain: Crl:WI Wistar rats
Source: Charles River Laboratories, Research Models and Services, Germany GmbH, Sandhofer Weg 7, D-97633 Sulzfeld, Germany
Hygienic level at arrival: SPF
Hygienic level during the study: Standard housing conditions
Number of animals: 9 animals, 3 animals/group
Sex: Female, nulliparous and non-pregnant
Age of animals at dosing: Young healthy adult rats, 8-10 weeks old
Body weight at treatment: 194 – 234 g
Acclimatisation period: At least 5 days
Husbandry
Animal health: Only healthy animals were used for the test. The health status was certified by the staff Veterinarian.
Number of animal room: 245/8
Housing: 3 animals / cage
Cage type: Type II. polypropylene/polycarbonate
Bedding and nesting: “Lignocel 3/4-S Hygienic Animal Bedding” and “Arbocel crinklets natural” nesting material produced by J. Rettenmaier & Söhne GmbH + Co.KG (D-73494 Rosenberg, Germany) were available to animals during the study.
Lighting period: 12 hours daily, from 6.00 a.m. to 6.00 p.m.
Temperature: 19.1 – 25.9 °C
Relative humidity: 31 – 65 %
Ventilation: 15-20 air exchanges/hour
Enrichment: Animals were housed by group to allow social interaction and with deep wood sawdust bedding to allow digging and other normal rodent activities.
The temperature and relative humidity were recorded twice daily during the acclimatisation period and throughout the study.
Food and Water Supply
Animals received ssniff® SM R/M "Autoclavable complete diet for rats and mice – breeding and maintenance" produced by ssniff Spezialdiäten GmbH, D-59494 Soest Germany (batch number: 285 17890, expiry date: 31 August 2017), ad libitum, and tap water from the municipal supply, as for human consumption from a 500 mL bottle, ad libitum. The food is considered not to contain any contaminants that could reasonably be expected to affect the purpose or integrity of the study.
Water quality control analysis is performed once every three months and microbiological assessment is performed monthly, by Veszprém County Institute of State Public Health and Medical Officer Service (ÁNTSZ, H-8201 Veszprém, József A. u. 36., Hungary).
Animal Identification
Animals were individually identified using numbers written on the tail with an indelible marker pen. The numbers were given on the basis of CiToxLAB Hungary Ltd.'s
Master File, for each animal allocated to the treatment groups. The cages were identified by cards, with information about study code, sex, dose group, cage number and individual animal numbers.
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- polyethylene glycol
- Details on oral exposure:
- The test item was freshly formulated at a concentration of 30 or 200 mg/mL in the vehicle, in the Pharmacy of CiToxLAB Hungary Ltd. on the day of administration.
The formulation container was stirred continuously up to finishing the treatment.
Vehicle: PEG 400 (polyethylene glycol 400)
Manufacturer: Sigma-Aldrich
Batch number: BCBS1795V
Expiry date: 31 May 2018 - Doses:
- Justification of the dose:
A limit test was not performed as the acute oral LD50 value of the test substance was expected to be 341 mg/kg bw in rats, based on the information provided by the Sponsor. A starting dose of 300 mg/kg bw was selected by the Study Director in agreement with the Sponsor.
Initially three animals were treated at the starting dose. As only one animal died, the dose of 300 mg/kg bw was repeated with three additional animals. As no animal died in the additional group at 300 mg/kg bw, the third group received a higher dose (2000 mg/kg bw). As each animal died in this dose group, further testing was not required according to the test guidelines (OECD 423, Commission Regulation (EC) No 440/2008 of 30 May 2008, B.1.tris). - No. of animals per sex per dose:
- 3 animals/group
- Control animals:
- no
- Details on study design:
- A single oral gavage administration was followed by a 14-day observation period. On the night before treatment, the animals were fasted. The food but not water was withheld during an overnight period. Animals were weighed just before treatment. The test item was administered by oral gavage in the morning. The food was returned 3 hours after the treatment.
OBSERVATIONS
Clinical Observations
Clinical observations were performed on all animals at 30 minutes, 1, 2, 3, 4 and 6 hours after dosing and daily for 14 days thereafter, where possible. Individual observations were performed on the skin, fur, eyes, mucous membranes, respiratory, circulatory, autonomic and central nervous system, somatomotor activity and behaviour pattern. Particular attention was directed to observation of tremors, convulsions, salivation, diarrhoea, lethargy, sleep and coma.
Body Weight Measurement
The body weight was recorded on the day before treatment (Day -1), on the day of the treatment (Day 0) and weekly thereafter, where possible.
NECROPSY
Macroscopic examination was performed on all animals. The animals were sacrificed by exsanguination under pentobarbital anaesthesia (Release, 30% pentobarbital sodium; Lot number: 106075, Expiry date: 31 July 2018, Produced by: Wirtschaftsgenossenschaft deutscher Tierärzte eG, Germany). After examination of the external appearance, the cranial, thoracic and the abdominal cavities were opened and the organs and the tissues were observed. Macroscopic abnormalities were recorded. - Statistics:
- The method used was not intended to allow the calculation of a precise LD50 value.
The test item was ranked into categories of Globally Harmonized Classification System (GHS (rev. 6) 2015). Clinical signs, body weight, body weight gain and gross macroscopic data were tabulated.
Results and discussion
Effect levels
- Key result
- Sex:
- female
- Dose descriptor:
- LD50
- Effect level:
- > 300 - < 2 000 mg/kg bw
- Based on:
- test mat.
- Mortality:
- PTSM caused mortality in 1 of 6 animals at a dose level of 300 mg/kg bw and in 3 of 3 animals at a dose level of 2000 mg/kg bw.
- Clinical signs:
- other: In the groups treated at a dose level of 300 mg/kg bw, hunched back (6/6), slight to moderate decreased activity (4/6), piloerection (3/6), slight to moderate incoordination (2/6) and wasted condition (2/6) were recorded. In the group treated at a dose le
- Gross pathology:
- Red or dark red diffuse discoloration of all lobes of the lung was found in the rats that died during the observation period.
No macroscopic findings were noted in the surviving animals at necropsy dosed at 300 mg/kg bw and terminated on Day 14. - Other findings:
- No further findings specified in the study report.
Any other information on results incl. tables
CLINICAL OBSERVATIONS
DOSE LEVEL: 300 mg/kg bw, Treatment on Day 0 |
|
|
|
|
|
|
|
|
|
SEX: FEMALE |
||||||
Cage No. |
Animal Number |
Observations |
Observation days |
Frequency |
||||||||||||
0 |
1 |
2 |
3 |
4 |
5 |
6 |
7-14 |
|||||||||
30’ |
1h |
2h |
3h |
4h |
6h |
|||||||||||
1 |
8789 |
Symptom free |
+ |
+ |
- |
- |
- |
- |
- |
- |
- |
- |
- |
+ |
+ |
11/20 |
Activity decreased |
- |
- |
1 |
1 |
1 |
1 |
1 |
2 |
2 |
2 |
1 |
- |
- |
9/20 |
||
Hunched back |
- |
- |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
- |
- |
9/20 |
||
Incoordination |
- |
- |
- |
- |
- |
- |
- |
1 |
- |
- |
- |
- |
- |
1/20 |
||
Piloerection |
- |
- |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
- |
- |
- |
8/20 |
||
Wasted |
- |
- |
- |
- |
-- |
- |
- |
- |
+ |
+ |
- |
- |
- |
2/20 |
||
8790 |
Symptom free |
+ |
+ |
- |
- |
- |
- |
- |
+ |
+ |
+ |
+ |
+ |
+ |
15/20 |
|
Activity decreased |
- |
- |
1 |
1 |
1 |
1 |
- |
- |
- |
- |
- |
- |
- |
4/20 |
||
Hunched back |
- |
- |
+ |
+ |
+ |
+ |
+ |
- |
- |
- |
- |
- |
- |
5/20 |
||
Piloerection |
- |
- |
+ |
+ |
+ |
+ |
+ |
- |
- |
- |
- |
- |
- |
5/20 |
||
8791# |
Symptom free |
+ |
+ |
- |
- |
- |
- |
- |
- |
- |
- |
|
|
|
2/10 |
|
Activity decreased |
- |
- |
1 |
1 |
1 |
1 |
1 |
2 |
2 |
2 |
|
|
|
8/10 |
||
Hunched back |
- |
- |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
|
|
|
8/10 |
||
Incoordination |
- |
- |
- |
- |
- |
- |
- |
2 |
- |
- |
|
|
|
1/10 |
||
Piloerection |
- |
- |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
|
|
|
8/10 |
||
Wasted |
- |
- |
- |
- |
- |
- |
- |
- |
+ |
+ |
|
|
|
2/10 |
||
Found dead |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
+ |
|
|
- |
||
2 |
8792 |
Symptom free |
+ |
+ |
+ |
- |
- |
- |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
17/20 |
Hunched back |
- |
- |
- |
+ |
+ |
+ |
- |
- |
- |
- |
- |
- |
- |
3/20 |
||
8793 |
Symptom free |
+ |
+ |
+ |
- |
- |
- |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
17/20 |
|
Hunched back |
- |
- |
- |
+ |
+ |
+ |
- |
- |
- |
- |
- |
- |
- |
3/20 |
||
8794 |
Symptom free |
+ |
+ |
+ |
- |
- |
- |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
17/20 |
|
Activity decreased |
- |
- |
- |
- |
1 |
1 |
- |
- |
- |
- |
- |
- |
- |
2/20 |
||
Hunched back |
- |
- |
- |
+ |
+ |
+ |
- |
- |
- |
- |
- |
- |
- |
3/20 |
||
DOSE LEVEL: 2000 mg/kg bw, Treatment on Day 0 |
|
|
|
|
|
|
|
|
|
SEX: FEMALE |
||||||
5 |
9311# |
Activity decreased |
1 |
2 |
|
|
|
|
|
|
|
|
|
|
|
2/2 |
Hunched back |
+ |
+ |
|
|
|
|
|
|
|
|
|
|
|
2/2 |
||
Prone position |
- |
+ |
|
|
|
|
|
|
|
|
|
|
|
1/2 |
||
Incoordination |
1 |
- |
|
|
|
|
|
|
|
|
|
|
|
1/2 |
||
Piloerection |
- |
+ |
|
|
|
|
|
|
|
|
|
|
|
1/2 |
||
Found dead |
- |
- |
+ |
|
|
|
|
|
|
|
|
|
|
- |
||
9312# |
Activity decreased |
1 |
1 |
2 |
2 |
|
|
|
|
|
|
|
|
|
4/4 |
|
Hunched back |
+ |
+ |
+ |
+ |
|
|
|
|
|
|
|
|
|
4/4 |
||
Prone position |
- |
- |
- |
+ |
|
|
|
|
|
|
|
|
|
1/4 |
||
Incoordination |
1 |
1 |
1 |
- |
|
|
|
|
|
|
|
|
|
3/4 |
||
Piloerection |
- |
+ |
+ |
+ |
|
|
|
|
|
|
|
|
|
3/4 |
||
Found dead |
- |
- |
- |
- |
+ |
|
|
|
|
|
|
|
|
- |
||
9313# |
Activity decreased |
1 |
2 |
|
|
|
|
|
|
|
|
|
|
|
2/2 |
|
Hunched back |
+ |
+ |
|
|
|
|
|
|
|
|
|
|
|
2/2 |
||
Incoordination |
1 |
1 |
|
|
|
|
|
|
|
|
|
|
|
2/2 |
||
Piloerection |
- |
+ |
|
|
|
|
|
|
|
|
|
|
|
1/2 |
||
Found dead |
- |
- |
+ |
|
|
|
|
|
|
|
|
|
|
- |
Remarks: + = present - = absent
h = hour ‘ = minute
# = Found dead
Frequency of observation = number of occurrence of observation/total number of observations
Severities: 1 = slight/small/few, 2 = moderate/medium, 3 = marked/large/many
BODY WEIGHT DATA
DOSE LEVEL: 300 mg/kg bw, Treatment on Day 0 |
SEX: FEMALE |
|||||||||
Cage No. |
Animal Number |
Body weight (g) |
Day/Body Weight (g) Death |
Body Weight Gain (g) |
||||||
Days |
||||||||||
-1 |
0 |
7 |
14 |
-1-0 |
0-7 |
7-14 |
-1-14 |
|||
1 |
8789 |
212 |
194 |
191 |
237 |
- |
-18 |
-3 |
46 |
25 |
8790 |
220 |
201 |
244 |
255 |
- |
-19 |
43 |
11 |
35 |
|
8791 |
215 |
194 |
- |
- |
5/140 |
-21 |
- |
- |
- |
|
2 |
8792 |
217 |
198 |
235 |
248 |
- |
-19 |
37 |
13 |
31 |
8793 |
233 |
218 |
238 |
259 |
- |
-15 |
20 |
21 |
26 |
|
8794 |
222 |
202 |
248 |
257 |
- |
-20 |
46 |
9 |
35 |
|
Mean: |
219.8 |
201.2 |
231.2 |
251.2 |
- |
-18.7 |
28.6 |
20.0 |
30.4 |
|
Standard deviation: |
7.4 |
8.9 |
23.0 |
9.0 |
- |
2.1 |
20.3 |
15.2 |
4.8 |
|
DOSE LEVEL: 2000 mg/kg bw, Treatment on Day 0 |
SEX: FEMALE |
|||||||||
5 |
9311# |
242 |
234 |
- |
- |
- |
-8 |
- |
- |
- |
9312# |
223 |
213 |
- |
- |
- |
-10 |
- |
- |
- |
|
9313# |
228 |
213 |
- |
- |
- |
-15 |
- |
- |
- |
|
Mean: |
231.0 |
220.0 |
- |
- |
- |
-11.0 |
- |
- |
- |
|
Standard deviation: |
9.8 |
12.1 |
- |
- |
- |
3.6 |
- |
- |
- |
- = No data
# = Found dead
NECROPSY FINDINGS
DOSE LEVEL: 300 mg/kg bw, Treatment on Day 0 |
SEX: FEMALE |
||||
Cage No. |
Animal Number |
Necropsy Date/ Necropsy Day |
External Observations |
Internal Observations |
Organ/Tissue |
1 |
8789 |
23 May 2017 Day 14 |
No external observations recorded |
No internal observations recorded |
Not applicable |
8790 |
23 May 2017 Day 14 |
No external observations recorded |
No internal observations recorded |
Not applicable |
|
8791# |
14 May 2017 Day 5 |
No external observations recorded |
Non collapsed |
Lungs |
|
Discoloration, red, diffuse, all lobes |
|||||
2 |
8792 |
30 May 2017 Day 14 |
No external observations recorded |
No internal observations recorded |
Not applicable |
8793 |
30 May 2017 Day 14 |
No external observations recorded |
No internal observations recorded |
Not applicable |
|
8794 |
30 May 2017 Day 14 |
No external observations recorded |
No internal observations recorded |
Not applicable |
|
DOSE LEVEL: 2000 mg/kg bw, Treatment on Day 0 |
SEX: FEMALE |
||||
5 |
9311# |
06 June 2017 Day 0 |
No external observations recorded |
Collapsed |
Lungs |
Discoloration, red, diffuse, all lobes |
|||||
9312# |
06 June 2017 Day 0 |
No external observations recorded |
Non collapsed |
Lungs |
|
Dark discoloration, red, diffuse, all lobes |
|||||
9313# |
06 June 2017 Day 0 |
No external observations recorded |
Non collapsed |
Lungs |
|
Discoloration, red, diffuse, all lobes |
# = Found dead
Applicant's summary and conclusion
- Interpretation of results:
- Category 4 based on GHS criteria
- Conclusions:
- Under the conditions of this study, the acute oral LD50 value of the test item PTSM was found to be between 300 and 2000 mg/kg bw in female Crl:WI rats.
According the GHS criteria, PTSM can be ranked as "Category 4" for acute oral exposure. - Executive summary:
The single-dose oral toxicity of PTSM was performed according to the acute toxic class method (OECD 423 and Commission Regulation (EC) No 440/2008 of 30 May 2008, B.1.tris) in Crl:WI rats.
Two groups of three female Crl:WI rats were treated with the test item at a dose level of 300 mg/kg bw (Group 1 and Group 2) and one group of three female Crl:WI rats at a dose level of 2000 mg/kg bw (Group 3).
A single oral treatment was carried out by gavage for each animal after an overnight food withdrawal. Food was made available again 3 hours after the treatment. The test item was administered formulated in PEG 400 at a concentration of 30 or 200 mg/mL at a dose volume of 10 mL/kg bw.
Initially, three females (Group 1) were treated at a dose level of 300 mg/kg bw. As only one animal was found dead, a confirmatory group (Group 2) was treated at the same dose level. As no animal died in the confirmatory group, the next dose level was 2000 mg/kg bw. As all animals were found dead in the group treated at a dose level of 2000 mg/kg bw (Group 3), no further testing was required according to OECD 423 and Commission Regulation (EC) No 440/2008 of 30 May 2008, B.1.tris.
Clinical observations were performed at 30 minutes, 1, 2, 3, 4 and 6 hours after dosing and daily for 14 days thereafter, where possible. Body weight was measured on Days -1, 0 and 7 and 14 (before necropsy), where possible. All animals were subjected to a necropsy and a macroscopic examination.
RESULTS
Mortality
PTSM caused mortality in 1 of 6 animals at a dose level of 300 mg/kg bw and in 3 of 3 animals at a dose level of 2000 mg/kg bw.
Clinical Observations
In the groups treated at a dose level of 300 mg/kg bw, hunched back (6/6), slight to moderate decreased activity (4/6), piloerection (3/6), slight to moderate incoordination (2/6) and wasted condition (2/6) were recorded.
In the group treated at a dose level of 2000 mg/kg bw, slight to moderate decreased activity (3/3), hunched back (3/3), slight incoordination (3/3), piloerection (3/3) and prone position (2/3) were seen before death.
Body Weight and Body Weight Gain
Treatment related body weight loss was observed in one of the surviving animals following treatment, but the animal recovered the lost weight during the second week of the observation period. The body weight changes of the animals died during the study could not be evaluated. The body weight of the other treated animals during the study showed no indication of a test item-related effect.
Macroscopic Findings
Red or dark red diffuse discoloration of all lobes of the lungs was found in the rats that died during the observation period.
No macroscopic findings were noted in the surviving animals at necropsy dosed at 300 mg/kg bw and terminated on Day 14.
CONCLUSION
Under the conditions of this study, the acute oral LD50 value of the test item PTSM was found to be between 300 and 2000 mg/kg bw in female Crl:WI rats.
According the GHS criteria, PTSM can be ranked as "Category 4" for acute oral exposure.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
